However, results from the RV144 trial showing predominant anti-Env CD4 responses [2], and the correlation between Env-specific antibodies and protection against HIV-1 infection [62] suggest that a vaccine able to elicit strong CD4+ T-cell responses against Env would be valuable in order to improve antibody-mediated protection. The gene discussed is ERVW-1; the disease is HIV-1 infection.